Matches in SemOpenAlex for { <https://semopenalex.org/work/W4229070082> ?p ?o ?g. }
- W4229070082 endingPage "1013" @default.
- W4229070082 startingPage "1005" @default.
- W4229070082 abstract "•SCCD has excellent inter-reader agreement and strongly correlates with spleen volume.•SCCD predicts hepatic decompensation in patients with compensated ACLD.•Impaired FLIS indicates an increased risk of ACLF in patients with decompensated ACLD.•An algorithm based on FLIS and SCCD efficiently stratifies mortality risk in patients with ACLD. Background & AimsFunctional liver imaging score (FLIS) – derived from gadoxetic acid-enhanced MRI – correlates with liver function and independently predicts liver-related mortality in patients with chronic liver disease (CLD), while splenic craniocaudal diameter (SCCD) is a marker of portal hypertension. The aim of this study was to investigate the accuracy of a combination of FLIS and SCCD for predicting hepatic decompensation, acute-on-chronic liver failure (ACLF), and mortality in patients with advanced CLD (ACLD).MethodsWe included 397 patients with CLD who underwent gadoxetic acid-enhanced liver MRI. The FLIS was calculated by summing the points (0-2) of 3 hepatobiliary-phase features: hepatic enhancement, biliary excretion, and portal vein signal intensity. Patients were stratified into 3 groups according to liver fibrosis severity and presence/history of hepatic decompensation: non-ACLD, compensated ACLD (cACLD), and decompensated ACLD (dACLD).ResultsSCCD showed excellent intra- and inter-reader agreement. Importantly, SCCD was an independent risk factor for hepatic decompensation in patients with cACLD (per cm; adjusted hazard ratio [aHR] 1.13; 95% CI 1.04-1.23; p = 0.004). Patients with cACLD and a FLIS of 0-3 points and/or a SCCD of >13 cm were at increased risk of hepatic decompensation (aHR 3.07; 95% CI 1.43-6.59; p = 0.004). In patients with dACLD, a FLIS of 0-3 was independently associated with an increased risk of ACLF (aHR 2.81; 95% CI 1.16-6.84; p = 0.02), even after adjusting for other prognostic factors. Finally, a FLIS and SCCD-based algorithm was independently predictive of transplant-free mortality and stratified the probability of transplant-free survival (TFS) in ACLD (p <0.001): FLIS 4-6 and SCCD ≤13 cm (5-year TFS of 84%) vs. FLIS 4-6 and SCCD >13 cm (5-year TFS of 70%) vs. FLIS 0-3 (5-year TFS of 24%).ConclusionThe FLIS and SCCD are simple imaging markers that provide complementary information for risk stratification in patients with compensated and decompensated ACLD.Lay summaryMagnetic resonance imaging (MRI) can be used to assess the state of the liver. Previously the functional liver imaging score, which is based on MRI criteria, was developed as a measure of liver function and to predict the risk of liver-related complications or death. By combining this score with a measurement of spleen diameter, also using MRI, we generated an algorithm that could predict the risk of adverse liver-related outcomes in patients with advanced chronic liver disease. Functional liver imaging score (FLIS) – derived from gadoxetic acid-enhanced MRI – correlates with liver function and independently predicts liver-related mortality in patients with chronic liver disease (CLD), while splenic craniocaudal diameter (SCCD) is a marker of portal hypertension. The aim of this study was to investigate the accuracy of a combination of FLIS and SCCD for predicting hepatic decompensation, acute-on-chronic liver failure (ACLF), and mortality in patients with advanced CLD (ACLD). We included 397 patients with CLD who underwent gadoxetic acid-enhanced liver MRI. The FLIS was calculated by summing the points (0-2) of 3 hepatobiliary-phase features: hepatic enhancement, biliary excretion, and portal vein signal intensity. Patients were stratified into 3 groups according to liver fibrosis severity and presence/history of hepatic decompensation: non-ACLD, compensated ACLD (cACLD), and decompensated ACLD (dACLD). SCCD showed excellent intra- and inter-reader agreement. Importantly, SCCD was an independent risk factor for hepatic decompensation in patients with cACLD (per cm; adjusted hazard ratio [aHR] 1.13; 95% CI 1.04-1.23; p = 0.004). Patients with cACLD and a FLIS of 0-3 points and/or a SCCD of >13 cm were at increased risk of hepatic decompensation (aHR 3.07; 95% CI 1.43-6.59; p = 0.004). In patients with dACLD, a FLIS of 0-3 was independently associated with an increased risk of ACLF (aHR 2.81; 95% CI 1.16-6.84; p = 0.02), even after adjusting for other prognostic factors. Finally, a FLIS and SCCD-based algorithm was independently predictive of transplant-free mortality and stratified the probability of transplant-free survival (TFS) in ACLD (p <0.001): FLIS 4-6 and SCCD ≤13 cm (5-year TFS of 84%) vs. FLIS 4-6 and SCCD >13 cm (5-year TFS of 70%) vs. FLIS 0-3 (5-year TFS of 24%). The FLIS and SCCD are simple imaging markers that provide complementary information for risk stratification in patients with compensated and decompensated ACLD." @default.
- W4229070082 created "2022-05-08" @default.
- W4229070082 creator A5001144757 @default.
- W4229070082 creator A5014851402 @default.
- W4229070082 creator A5015345650 @default.
- W4229070082 creator A5024485263 @default.
- W4229070082 creator A5024856763 @default.
- W4229070082 creator A5029138179 @default.
- W4229070082 creator A5034914777 @default.
- W4229070082 creator A5044446362 @default.
- W4229070082 creator A5044894220 @default.
- W4229070082 creator A5046244856 @default.
- W4229070082 creator A5055031891 @default.
- W4229070082 creator A5062078348 @default.
- W4229070082 creator A5067605507 @default.
- W4229070082 creator A5067755783 @default.
- W4229070082 creator A5069560637 @default.
- W4229070082 creator A5080825841 @default.
- W4229070082 creator A5087316703 @default.
- W4229070082 creator A5090751499 @default.
- W4229070082 date "2022-10-01" @default.
- W4229070082 modified "2023-09-25" @default.
- W4229070082 title "Gadoxetic acid-enhanced MRI-derived functional liver imaging score (FLIS) and spleen diameter predict outcomes in ACLD" @default.
- W4229070082 cites W1905695250 @default.
- W4229070082 cites W1993195087 @default.
- W4229070082 cites W2000123032 @default.
- W4229070082 cites W2000207023 @default.
- W4229070082 cites W2007670274 @default.
- W4229070082 cites W2026147737 @default.
- W4229070082 cites W2088029436 @default.
- W4229070082 cites W2101099470 @default.
- W4229070082 cites W2128571010 @default.
- W4229070082 cites W2130601804 @default.
- W4229070082 cites W2134135099 @default.
- W4229070082 cites W2163656263 @default.
- W4229070082 cites W2289440019 @default.
- W4229070082 cites W2325644798 @default.
- W4229070082 cites W2391280674 @default.
- W4229070082 cites W2530578904 @default.
- W4229070082 cites W2546046192 @default.
- W4229070082 cites W2550258761 @default.
- W4229070082 cites W2784907329 @default.
- W4229070082 cites W2800551238 @default.
- W4229070082 cites W2883876884 @default.
- W4229070082 cites W2884374410 @default.
- W4229070082 cites W2907520153 @default.
- W4229070082 cites W2936182851 @default.
- W4229070082 cites W2990268779 @default.
- W4229070082 cites W3007189276 @default.
- W4229070082 cites W3010121905 @default.
- W4229070082 cites W3036900290 @default.
- W4229070082 cites W3083445887 @default.
- W4229070082 cites W3136523694 @default.
- W4229070082 cites W3137042396 @default.
- W4229070082 cites W3165072581 @default.
- W4229070082 cites W3174905293 @default.
- W4229070082 cites W4292405063 @default.
- W4229070082 cites W571628560 @default.
- W4229070082 doi "https://doi.org/10.1016/j.jhep.2022.04.032" @default.
- W4229070082 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35525337" @default.
- W4229070082 hasPublicationYear "2022" @default.
- W4229070082 type Work @default.
- W4229070082 citedByCount "8" @default.
- W4229070082 countsByYear W42290700822022 @default.
- W4229070082 countsByYear W42290700822023 @default.
- W4229070082 crossrefType "journal-article" @default.
- W4229070082 hasAuthorship W4229070082A5001144757 @default.
- W4229070082 hasAuthorship W4229070082A5014851402 @default.
- W4229070082 hasAuthorship W4229070082A5015345650 @default.
- W4229070082 hasAuthorship W4229070082A5024485263 @default.
- W4229070082 hasAuthorship W4229070082A5024856763 @default.
- W4229070082 hasAuthorship W4229070082A5029138179 @default.
- W4229070082 hasAuthorship W4229070082A5034914777 @default.
- W4229070082 hasAuthorship W4229070082A5044446362 @default.
- W4229070082 hasAuthorship W4229070082A5044894220 @default.
- W4229070082 hasAuthorship W4229070082A5046244856 @default.
- W4229070082 hasAuthorship W4229070082A5055031891 @default.
- W4229070082 hasAuthorship W4229070082A5062078348 @default.
- W4229070082 hasAuthorship W4229070082A5067605507 @default.
- W4229070082 hasAuthorship W4229070082A5067755783 @default.
- W4229070082 hasAuthorship W4229070082A5069560637 @default.
- W4229070082 hasAuthorship W4229070082A5080825841 @default.
- W4229070082 hasAuthorship W4229070082A5087316703 @default.
- W4229070082 hasAuthorship W4229070082A5090751499 @default.
- W4229070082 hasBestOaLocation W42290700821 @default.
- W4229070082 hasConcept C126322002 @default.
- W4229070082 hasConcept C126838900 @default.
- W4229070082 hasConcept C143409427 @default.
- W4229070082 hasConcept C207103383 @default.
- W4229070082 hasConcept C2777214474 @default.
- W4229070082 hasConcept C2778659479 @default.
- W4229070082 hasConcept C2778721985 @default.
- W4229070082 hasConcept C2779102576 @default.
- W4229070082 hasConcept C2911208848 @default.
- W4229070082 hasConcept C44249647 @default.
- W4229070082 hasConcept C71924100 @default.
- W4229070082 hasConcept C90924648 @default.
- W4229070082 hasConceptScore W4229070082C126322002 @default.